Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...
Arrowhead Pharmaceutical’s investigational RNA interference (RNAi) obesity candidate in combination with Eli Lilly’s Zepbound ...
RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...
Arrowhead Pharmaceuticals today announced interim results from two Phase I/IIa clinical trials of ARO-INHBE and ARO-ALK7, the ...
Patients receiving concomitant PCSK9 inhibitor therapy experienced greater LDL cholesterol reductions, exceeding 50% during ...
Stocktwits on MSN
Why did ARWR stock surge over 15% pre-market today?
INHBE, especially when combined with tirzepatide, doubled weight loss and tripled reductions in visceral fat. ・In adults with ...
2d
Arrowhead Pharmaceuticals Touts Rudemplo Launch, Obesity RNAi Data and $920M Cash at JPM Conference
Arrowhead Pharmaceuticals (NASDAQ:ARWR) used its presentation at the JPMorgan Healthcare Conference to highlight a newly launched RNA interference (RNAi) therapy, a broad clinical-stage pipeline, and ...
With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship manufacturing facility in Massachusetts. Alnylam plans to spend $250 million in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback